China Pharma Holdings Gross Profit

China Pharma Holdings (CPHI) currently reports a gross profit of $180B as of June 2026. That compares with $-660B in the prior-year period — up 127.1% year over year. That is above the Healthcare sector average of $67B. Use the charts on this page to explore China Pharma Holdings's gross profit history and peer comparisons.

China Pharma Holdings's gross profit increased from $-660B to $180B — a 127.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

China Pharma Holdings's gross profit of $180B is higher than the Healthcare sector average of $67B. That is roughly 164.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

China Pharma Holdings reported $180B in gross profit as of June 2026. That compares with $-660B in the prior-year period — up 127.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $180B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $67B. From there, open related valuation or income-statement pages for China Pharma Holdings, and consider following CPHI for alerts when major investors trade the stock.